Home > Insider Trading > Filing (0000899243-22-031420)

Filing Details

Accession Number:: 0000899243-22-031420
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-09-19 06:06:19
Reporting Period:: 2022-09-15

Accepted Time:: 2022-09-19 06:06:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1832415	Better Therapeutics Inc.	BTTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1105941	P David Perry	C/O Better Therapeutics, Inc. 548 Market Street, #49404 San Francisco CA 94104	See Remarks	Yes	Yes	Yes	No
1890678	Trust 2015 Perry P. David	C/O Better Therapeutics, Inc. 548 Market Street, #49404 San Francisco CA 94104		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-09-15	10,844	$1.99	62,380	No	4	P	Direct
Common Stock	Acquisiton	2022-09-16	39,156	$2.07	101,536	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	293,150	Indirect	By spouse
Common Stock	21,336	Indirect	By Pensus Limited Trust
Common Stock	10,464,015	Indirect	By David P. Perry 2015 Trust

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.99 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Reflects the correction of an immaterial error in Column 5 reported in the Reporting Person's Form 4 filed on November 1, 2021.
These shares are owned directly by Mr. Perry's spouse, Georgianna Maule-Ffinch.
These shares are owned directly by Donald R. Leo, Trustee of Pensus Limited Trust dated 06/12/2010 FBO Georgianna Maule-Ffinch (the "Pensus Limited Trust") for the benefit of Georgianna Maule-Ffinch.
These shares are owned directly by the David P. Perry 2015 Trust (the "Perry Trust"), a ten percent owner of Issuer, and indirectly by Mr. Perry as trustee of the Perry Trust. Mr. Perry is an officer, director and ten percent owner of the Issuer.